Allergan Wins Right to Market Anti-Acne Drug
IRVINE — Allergan Inc. has won U.S. and Canadian marketing rights to an anti-acne medication sold in Europe by Schering AG of Germany, the company said Monday.
Herbert Laboratories, the skin care division of Allergan, will begin clinical studies on the topical compound, azelaic acid, and seek FDA approval, a process expected to take at least three years, said Allergan spokesman Jeff D’Eliscu.
Schering has been marketing azelaic acid as Skinoren cream in Europe, the company said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
